Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft synthesis: Dual and triple incretin receptor agonists… — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-098/3
Series
Public comment period
Version
1.0
Published
23 Mar 2026
Last reviewed
23 Mar 2026
Next review
23 Mar 2027
Identifier
10.71829/cei.cp.98
Certainty
Not rated
Cycle
2026 Q1
Window
30 Jan 2026 – 13 Mar 2026
Status
Closed
Submissions
7

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-DUAL-VS-SING/001Ms Rhiannon Okoye-VandergraafPatient-reported outcomes are collected by the trials and not reported by the reviewAccepted in part
DRAFT-DUAL-VS-SING/002Thaddeus Isaksen-BalogunThe timepoint at which each outcome was extracted was chosen after the data were seenAccepted
DRAFT-DUAL-VS-SING/003Dr Melisande Kirkpatrick-OlaThe review question is drawn too broadly to be answerableNot accepted
DRAFT-DUAL-VS-SING/004Dr Leonhard QuennevilleThe document should state what a reader ought to doNot accepted
DRAFT-DUAL-VS-SING/005Dr Quentin EnthovenStudies not published in English were excluded without assessmentAccepted in part
DRAFT-DUAL-VS-SING/006Stellan Cholmondeley-AdeReferences should carry a persistent identifier for every cited sourceAccepted in part
DRAFT-DUAL-VS-SING/007Dr Kolawole Isaksen-BalogunA funnel plot is presented for a set too small to interpret itAccepted
7 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted2The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part3Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment0The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted2The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Patient-reported outcomes are collected by the trials and not reported by the review — arising from DRAFT-DUAL-VS-SING/001. Patient-reported outcomes measured by any contributing trial are now reported narratively by instrument, with the instrument named and its minimum important difference stated where one is published, and the absence of a pooled estimate explained.
  2. The timepoint at which each outcome was extracted was chosen after the data were seen — arising from DRAFT-DUAL-VS-SING/002. The extraction timepoint is now prespecified in the protocol for new reviews. Where a review predates the requirement, estimates are reported at every timepoint the contributing trials report.
  3. Studies not published in English were excluded without assessment — arising from DRAFT-DUAL-VS-SING/005. Language restriction is removed from the protocol for the series, the records previously excluded on that ground are listed with their screening outcome, and the residual limitation is stated in the abstract of this review.
  4. References should carry a persistent identifier for every cited source — arising from DRAFT-DUAL-VS-SING/006. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
  5. A funnel plot is presented for a set too small to interpret it — arising from DRAFT-DUAL-VS-SING/007. The funnel plot is removed for every outcome contributed by fewer than ten studies, and replaced by a statement that small-study effects could not be assessed at that number, together with the count of registered trials identified without posted results.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.